WO2009005546A1 - High efficiency mouthpiece/adaptor for inhalers - Google Patents
High efficiency mouthpiece/adaptor for inhalers Download PDFInfo
- Publication number
- WO2009005546A1 WO2009005546A1 PCT/US2008/002989 US2008002989W WO2009005546A1 WO 2009005546 A1 WO2009005546 A1 WO 2009005546A1 US 2008002989 W US2008002989 W US 2008002989W WO 2009005546 A1 WO2009005546 A1 WO 2009005546A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aerosol
- inhaler
- particle
- mouthpiece
- airway
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/11—Laminar flow
Definitions
- Effective delivery to a patient is a critical aspect of any successful drug therapy.
- Subcutaneous injection is frequently an effective route for systemic drug delivery, but enjoys a low patient acceptance.
- Aerosol therapy constitutes a major part of the therapeutic treatment for patients with lung disease such as asthma and bronchitis, and has potential for the system delivery of insulin, peptides and proteins as well (Patton and Platz, 1992).
- the metered- dose inhaler (MDI) and dry-powder inhaler (DPI) are popular devices used in aerosol therapies.
- Particle deposition in the human respiratory tract is a complicated process involving effects of fluid dynamic and particle dynamics, and complications of anatomy. It is generally agreed that the relatively high velocity and the abrupt changes in flow direction in the oral airway are the primarily responsible for the inertia deposition of particles larger than 1 ⁇ m in diameter. There are many parameters that affect the aerosol deposition in the human oral air ways, some of theses are very well studied and documented, such as a particle size, particle density, and the respiratory flow rate.
- Inertial impaction is primarily responsible for the deposition in the oral cavity. Many parameters can influence the particle impaction such as particle size, air flow rate, plume characterization (Barry and O'Callaghan, 1997), mouth piece diameter (Lin, et al., 2001) and the type of the propellant used in the pressurized Metered Dose Inhaler (pMDI) (Cheng, Fu, Yazzie and Thou, 2001).
- Chlorofluorocarbon (CFC) pressurized Metered Dose Inhaler (pMDI) has a quite different deposition patterns than Hydrofluorocarbon (HFA) pMDI.
- HFA inhalers have lower deposition in the oral region than the CFC inhalers at all respiratory flow rates, and correspondingly improve the lung deposition.
- Aerosol initial conditions vary by different inhaler designs.
- the major problem associated with aerosol drug inhalers is the massive deposition of aerosol drugs on the back of throat. Since it is generally known that the inertial impaction is a dominant mechanism for aerosol deposition in oropharyngeal airways, the reduction of the impaction parameter (i.e., a function of size and velocity only) for inhaled aerosols become the focus of the prior research as well as aims of new inhaler design. Effects of initial positions are largely neglected in the literature although effects of aerosol size, velocity and breath patterns are well studied.
- particle initial condition was not deemed as a control parameter for prior industrial hygiene studies since subjects were expected to breath naturally in the experiments. While this parameter could be the dominant factor in aerosol therapy.
- various aerosol therapy strategies i.e., open-mouth vs. close-mouth method, the distance between inhaler and mouth, shape and opening o f the mouth, breath control, etc.
- various inhaler and spacer design i.e., cross-sectional geometry, spray angle, propellant pressure, etc.
- Lin et al. (2001) reported an experimental work on the effects of mouthpiece diameter on deposition efficiency in an oral airway cast. Their results showed that the effects were significant and depend on particle size. Lin et al. (2001) pointed out that the diameter may alter the airflow characteristics (i.e., air velocity and turbulence) for a given flow rate, leading to difference in deposition efficiency. In fact, the diameter will not only alter the airflow patterns, but also change the initial positions of inhaled aerosols relative to the oropharyngeal airway passage. Their experiments strongly supported our hypothesis that to manipulate inhaler designs can have significant effects on aerosol delivery efficiency.
- Deposition sites of inhaled aerosol medicines are mostly influenced by levels of respiratory intensity as defined by coupled tidal volumes and breathing frequencies and particle parameters such as geometric size, shape, and density.
- the phenomenon of particle deposition in the human airways are strongly affected by the very nature of the fluid motion in which they are entrained and transported.
- the total amount of aerosol deposited in the human lung can be represented as the product of aerosol volumetric concentration, respiratory volumetric flow rate and lung particle Deposition efficiency.
- human oral airway geometry consists of three parts. Part one has fifteen segments, each segment or slice has thickness of 3 mm. All the segments in part one have been sliced perpendicular on the Y axis, so each segment has constant Y value (Some of the sections are seen as Figs. 34 A-H) shows all the cross section shapes in the part one for scale factor one. Part two has eighteen segments, each segment or slice has been sliced every 5 degree. All the segments in part two have been sliced perpendicular on the 0 axis (cylindrical coordinates), so each segment has constant 0 value. (See Figs 35 A-L) shows all the cross section shapes in the part two for scale factor one.
- Part three has twenty eight segments, each segment or slice has thickness of 3 mm. All the segments in part one have been sliced perpendicular on the Z axis, so each segment has constant Z value. (See Figure 36K-L)shows all the cross section shapes in the part one for scale factor one.
- This oral geometry has been supplied to us by Lovelace Respiratory Research Institute, Albuquerque, NM. This human oral airway geometry represents a normal oral airway position not the oral airway during the inhalation process.
- Tongue position has a great influence on the deposition in the human airway.
- the tongue can take different positions according to the mouth opening and the respiratory flow rate. As we can see in Figure 27(#69-See part 3, Figure 27), the tongue can take different positions and different shapes, these positions/shapes will influence the deposition efficiency of the aerosol drug such as pMDI.
- the objective of this project is to understand the characteristics of respiratory flow and particle transportation patterns during aerosol therapy and to develop a high efficiency, portable, light, reliable, inexpensive, disposable, adaptable and easy-to-use ancillary devices for use with various aerosol therapy system, especially for inhalers.
- This will be conducted by means of computer simulations and experimental investigations using extrathoracic airway models.
- the specific aims of the study are a) to identify and quantitate those components of aerosol therapy that are subject to manufacture manipulations and/or spatient use, b) to optimize the inhaler mouthpiece configurations design, and c) to improve the efficiency of aerosol delivery by a minimum of 200% (i.e., from current average of 10% to 30%), within the typical range of respiratory flow rate and aerosol size encountered during aerosol therapy.
- Aerosols emitted from various cross-sectional location of mouthpiece have different destinations as demonstrated in our computer simulation.
- the efficiency of drug delivery can be significantly improved if an ancillary device (such as a specially configurated extended mouthpiece) is used to channel aerosols from where they are most likely to penetrate through the extrathoracic airways.
- This objective can be achieved by a good design of inhaler ancillary devices, including design of cross-sectional configuration, outside diameter, tapered angle, and distance extended into the mouth. Aerosol delivery efficiency is defined as the number ratio of the aerosols that went through the extrathoracic airways to the aerosols that ejected from the inhaler.
- the focus of the invention is the reduction of the aerosol deposition in extrathoracic airways, specifically, the oral-pharyngeal-laryngeal (OPL) airways.
- the proposed optimized inhaler configuration may or may not change (positively or negatively) the aerosol deposition patterns beyond the OPL airways.
- the OPL airways act as the first of a series of artificial filters that aerosol will encounter before reaching the targeted lower airway lung region. It should be the first and necessary problem to be addressed.
- aerosol velocities and sizes decrease drastically after the spray. Typically, the measured velocities are about 50 m/s at the nozzle orifice and close to 20 m/s when reach the back of throat.
- One object of this invention is to understand the characteristics of respiratory flow and particle transportation patterns during aerosol therapy and to develop a high efficiency, portable, light, reliable, inexpensive, disposable, adaptable and easy-to-use ancillary devices for use with various aerosol therapy system, especially for inhalers. This will include computer simulations and experimental investigations using extrathoracic airway models.
- the specific aims of the study are a) to identify and quantitate those components of aerosol therapy that are subject to manufacture manipulations and/or spatient use, b) to optimize the inhaler mouthpiece configurations design, and c) to improve the efficiency of aerosol delivery by a minimum of 200% (i.e., from current average of 10% to 30%), within the typical range of respiratory flow rate and aerosol size encountered during aerosol therapy.
- Another objective is design an innovative nozzle shape design for the drug inhaler.
- the purpose of the nozzle design is to launch/spray the particles from where they are most likely to go deep into the lung and therefore reduce the unwanted aerosol deposition in the throat.
- FIG. 1 is a schematic of various inhaler mouthpiece configurations
- FIG. 2 is a spray jet spreading structure
- FIG. 3 illustrates the velocity profiles in an oral passage at an inspiratory flow rate of 15 L/min, which corresponds to the breathing rate at a light activity condition;
- FIG.4 is a map of particle destination distribution;
- FIGS. 5A and 5B show a schematic particle generation systems;
- FIG. 6 shows a fabricated airway cast;
- FIG. 7 shows a fabricated airway cast
- FIG. 8 is a breakaway of an inhaler nozzle
- FIGS. 9A-C are a front end view, a sectional view and rear end view of FIG. 8, respectively;
- FIGS. 10 are a front end view, a sectional view and rear end view of an alternative embodiment, respectively;
- FIGS. 1 IA-C are a front end view, a sectional view and rear end view of an alternative embodiment, respectively;
- FIGS. 12A and B are front and rear views of still an alternative embodiment
- FIG. 13 is an oral airway model consisting of the mouth cavity, the pharyngeal cavity and the pharynx ;
- FIG. 14 the three different parts of the airway geometry
- FIG. 15 shows the oral airway clay segments
- FIG. 16 shows a human oral airway mold and cast
- FIG. 17 a dummy commercial inhaler
- FIG. 18 a canister charging system
- FIG. 19 illustrates experimental apparatus
- FIG. 20 is a measurement calibration curve
- FIG. 21 is a line graph of flow rate of a mouthpiece having a Diameter of 20mm;
- FIG. 22 is a line graph of flow rate of a mouthpiece having a Diameter of 16mm
- FIG. 23 is a line graph of penetration efficiency
- FIG. 24 is a line graph of the diameter effects of a flow rate of 90 L/min
- FIG. 25 is a line graph of the diameter effects of a flow rate of 60 L/min
- FIG. 26 is a line graph of the diameter effects of a flow rate of 30 L/min.
- FIG. 27 is a line graph of particle penetration efficiency
- FIG. 28 is a line graph of particle penetration efficiency
- FIG. 29 is a line graph of particle penetration efficiency
- FIG. 30 is a line graph of particle penetration efficiency
- FIG. 31 is a line graph of particle penetration efficiency
- FIG. 32 is a line graph of particle penetration efficiency
- FIG. 33 is a line graph of particle penetration efficiency
- FIG. 34A-H are cross sections of a human airway ;
- FIG. 35 A-L are cross sections of a human airway
- FIG. 36 A-L are cross sections of a human airway
- FIG. 37A-H illustrate different positions of a tongue
- FIG. 38 are three positions of tongues:
- FIG. 40 is a graph of aerosol penetration efficiencies with a need structure
- FIG. 41 show various inhaler adaptors made of straight channels with upward, angl-cuts of various degrees
- Aerosols emitted from various cross-sectional location of mouthpiece have different destinations.
- the efficiency of drug delivery can be significantly improved if an ancillary device (such as a specially configurated extended mouthpiece) is used to channel aerosols from where they are most likely to penetrate through the extrathoracic airways which can be achieved by a good good design of inhaler ancillary devices, including design of cross-sectional configuration, outside diameter, tapered angle, and distance extended into the mouth.
- Aerosol delivery efficiency is defined as the number ratio of the aerosols that went through the extrathoracic airways to the aerosols that ejected from the inhaler.
- the focus is the reduction of the aerosol deposition in extrathoracic airways, specifically, the oral-pharyngeal-laryngeal (OPL) airways.
- OPL oral-pharyngeal-laryngeal
- aerosol velocities and sizes decrease drastically after the spray.
- the measured velocities are about 50 m/s at the nozzle orifice and close to 20 m/s when reach the back of throat.
- aerosols can survive the OPL airways and enter thoracic region, their velocities and sizes are greatly reduced. A much smaller impaction force can be expected downstream.
- Fig. 1 shows the schematic drawings of various inhaler mouthpiece configurations. "Close-mouth' method, in which the lip encloses a mouthpiece, is used for the purpose of demonstration.
- Fig. IA shows a typical design of an existing inhaler mouthpiece configuration. Most current inhaler mouthpiece has a circular or an oval cross sectional geometry with uniform tube thickness.
- Panel B of Fig. 1 demonstrates an improved cross sectional configuration design that might improve aerosol delivery efficiency.
- the inner cross-sectional shape of the mouthpiece matches the contours of particle penetration zone revealed from computer simulation and experimental verification, while the outer configuration might still maintain the circular geometry for manufacture convenience or patient comfort.
- the mouthpiece has sloped roof configuration facing the downward direction.
- the mainstream air levels out while the entrained aerosols near the top will continue their downward motions due to inertial forces. These are the same forces causing the aerosols deposited on the back of the throats.
- the downward angle will facilitate particles passing through the 90-degree downward bend of the oropharyngeal airway. Therefore, it will reduce the deposition at the back of throat caused by particle inertial impaction.
- This design is a three-dimensional optimization: 1 ) the inner passage can has a variable as well as a simple linearly sloped cross-sectional geometry, 2) aerosols enter the mouth in a downward direction, 3) this design can be achieved by design a 3-D optimum mouthpiece adaptor connected with most existing mouthpiece, 4) a simple version of the 3-D design can be achieved by placing a 2-D optimized plate configuration in front of a: straight downward regular circular tube.
- a preferred embodiment of the inhaler mouthpiece configuration is displayed in Panel D of Fig. 1.
- the inhaler distance extended into the oral cavity as well as the outer diameter of the mouthpiece is also optimized. It is noted that for most conventional designs, the distance of inhaler intruded into the mouth not only varies between patient to patient, but also changes between every therapy for the same individual.
- the outer diameter of a mouthpiece also plays an important role by controlling the opening of the mouth, therefore, it affects the shape of oral cavity.
- inhaler and spacers There is a wide range of brands of inhaler and spacers available on the market. In principle, the aforementioned design concepts can be applied to all aerosol medicine delivery system, including MDI, DPI, nebulizer, as well as spacers and chambers. It is desired to have a universal inhaler ancillary device. Essentially, this device is a hollow, flexible and has an extended mouthpiece with an optimum configuration. It will easily hook up to mouthpieces of most current inhalers, spacers and other aerosol delivery systems. The optimum mouthpiece configuration assures high efficiency while extension places the inhaler at a greater distance from the mouth and thus further diffuses the aerosol velocity. The hollow and see-through structure minimizes the drug loses in the device and simplifies clean up.
- the inhaler adaptor design is high efficiency, portable, light, reliable, inexpensive, disposable, adaptable and easy-to-clean. It is also designed to universally fit most aerosol therapy systems, especially for portable inhalers.
- the design features are described as follows: 1. Adaptor design with a slightly upward angle.
- the commercial inhaler PROVENTIL MDI
- PROVENTIL MDI is used in the experiments to mimic the realistic inhaler spray.
- the suspension of dry green fluorescent polymer micro spheres of 7 micron (Duke Scientific, Corp., Excitation 468 nm; Emission 508 nm) and R134-a are charged into the PROVENTIL canister.
- Various (5) kinds of tests are conducted repeatedly throughout the experiments to assure the accuracy and consistency of the experimental system.
- a significant improvement in aerosol delivery efficiency can be obtained by using a novel spray jet spreading structure shown in Figure 2.
- the experiments are conducted at the typical aerosol therapy condition with the respiratory flow rate at 30 L/min and particle diameter equal 7 micron, respectively.
- Test shows a significant enhancement in overall efficiency, from 15% to 33%, and in oral delivery efficiency, from 15% to 55%.
- the model of the human oral airway tract begins at the mouth entrance and continues through oral cavity, pharynx, larynx, and ending at the trachea.
- the cross-sections of the airway passages are based on the geometry published by Cheng et al. (1997), which is the identical geometry used in the computer simulation.
- the oral portion of the airway system was molded from a dental impression of the oral cavity from a human volunteer, while the other airway portions were modeled from a cadaver.
- the hollow airway rubber model was obtained by removing the wax in boiling water.
- the inside surface of the airway model was coated with an aqueous solution (Lin et al., 2001) containing 1% carboxymethylcellulose sodium (Spectrum Chemical Mfg. Corp., Gardena, CA) to simulate the mucus layer and to minimize the particle bounce.
- Fig. 3 shows the velocity profiles in an oral passage at an inspiratory flow rate of 15 L/min, which corresponds to the breathing rate at a light activity condition.
- the condition of free inhalation (or without the mouthpiece) and steady breathing were simulated.
- Various characteristics of oral airway flows, including boundary layer flows, creeping flows, bend flows and jet flows were clearly displayed.
- Fig. 4 displays a map of particle destination distribution. Aerosols were inhaled through a mouthpiece attached to the inhaler. The mouthpiece/spacer had a circular cross sectional geometry and was attached to the mouth (or zero distance extended into the oral cavity). The map was compiled based on the results of some 400-particle trajectories at inspiratory flow rate of 45 L/min and particle size of fourteen microns. Inert particles with breath-activated conditions were simulated. The aerosol entering condition corresponds to dry-powder inhaler (DPI) applications, where aerosol initial velocities were approximately the same as flow velocity, and particle sizes are relative large.
- DPI dry-powder inhaler
- the concept of an optimum design is such that a high efficiency inhaler ancillary device will be able to guide particles to where they are most likely to penetrate extrathoracic airways, and therefore reduce unwanted aerosol deposition in the oral passages.
- the objective of the prevailing inhaler design is to reduce the aerosol impaction parameter (or to reduce particle size, mass and velocity).
- Typical cross-sectional geometry of inhaler nozzles is of a circular or oval shape.
- the shape of the mouth opening bears the peripheral shape of the inhaler mouthpiece. This may not be the optimum shape of the inhaler design.
- FIG. 5 A schematic of the experimental setup is shown in Fig. 5.
- Two kinds of particle generation systems were used in the experiments to simulate two different type of aerosol delivery system. They are shown in Fig. 5, Panel A. Breath-activated System and Panel B. Propellant-driven System, respectively.
- the initial velocity of a breath-activated aerosol was approximately the same as that of the flow at the oral entrance. Aerosol inhalation through a mouthpiece or spacer attached to the inhaler can be approximated as breath-activated system.
- Monodisperse polystyrene fluorescent microspheres (specific gravity of 1.05) suspended in distilled water are atomized and dried within a Tri-Jet Aerosol Generator (Thermal System Inc.).
- the fluorescent particles exiting the aerosol generator were first neutralized by using an aerosol neutralizer (Richmond Static Control) and mixed with a steady flow of filtered room air. The flow then entered into the experimental containment where it was uniformly dispersed by a small mixing fan mounted within the box.
- the experimental box was a plexi-glass holding unit for most of the airway cast.
- the trachea extends outside the box through a hole in the bottom surface.
- the box also includes six holes that allow the positioning of particle sampling probes throughout the unit.
- An inhaler spacer/mouthpiece with tapered cross sectional geometry similar to the predicted profiles of passing-through zone were placed inside (or in front) of mouth entrance.
- the trachea was the last segment of the experimental respiratory system, and this is where the exhaustion concentration readings were taken.
- the flow then entered a 3.5 in (8.9 cm) diameter hard plastic duct that connects to a filter.
- the exit duct was connected to a blower, which draws air through the experimental airways to simulate inhalation from a person breathing.
- a flow meter was placed at the outlet of the blower to measure the volumetric flow rate, which was controlled by regulating the voltage supplied to the blower motor. For transient experiments, a breather replaced the blower.
- the Multi-Channel Monitor contains a 7805-5 input board that has eight input channels, which are each set to record various particle size readings. The data that was collected by the Multi-Channel Monitor and sent every 84 seconds to an IBM computer, which stored the data for future analysis.
- the MDI inhaler was used for the experiments with propellant-driven aerosol generator system. These aerosol inhalers were provided by pharmaceutical companies. These aerosol inhalers were mounted on inhaler trigger devices to imitate the coordination of hand action and inhalation. The trigger actions were controlled by solenoid valves. The actuation time of the solenoid valve were controlled by a personal computer (PC). The distances/angles between the inhaler and mouth were easily adjusted to duplicate actual inhaler applications.
- PC personal computer
- a filter (WI) was placed in one line and the airway model was placed in another line followed by a filter (W2). Identical flow rates were used in both lines during the experiments.
- the desirable cyclic air movement through the surrogate airway casts was induced by the reciprocating motion of a piston in a piston-cylinder type device called a human breath simulator.
- the motion of the piston was actuated by a linear motor, which is in turn was controlled by electrical signal input. These electrical signals were converted from different breath profiles displayed on the PC screen.
- the particles were collected on the aforementioned filters for 10 - 20 minutes.
- the particles deposition values were obtained by measuring the weight of filters Wl and W2.
- An OHAUS Model AP210S precision analytical scale will be employed.
- the accuracy and readability of the scale was 10e-5 gram.
- CFX 5.1 (AEA Technology Inc., Pittsburgh, PA) was used. It is general-purpose software for fluid flow simulation consisting of pre-processor, solver, and postprocessor. All kinds of flow scenarios can be modeled and the user can choose among a variety of solution techniques.
- CFX-3D is one of the leading CFD software that comprises decades of research and development. Therefore, much of discussion herein refers to and is adapted from the CFX 5.1 Flow Solver User Guide (2001). The following description of the modeling will concentrate on the work that needs customized coding and user input.
- the respiratory air stream is treated as viscous, homogeneous, and incompressible fluid. Its motion is governed by the Navier-Stokes equations (consisting of three partial differential equations in a three-dimensional coordinate system) and the continuity equation. In order to solve these equations numerically, these continuous differential equations must be discretized on the grid nodes distributed within the airway geometry by using various approximation methods to obtain a system of simplified algebraic equations.
- the control-volume scheme based on the principals of mass, energy and momentum conservation is mainly used in CFX-3D software for numerical discretization.
- the extrathoracic airflows consist of both laminar and turbulent flows. Generally speaking, most laminar flows problem can be numerically solved without encountering major difficulties. However, turbulent flow problems are most difficult to analyze. It is almost impossible to directly simulate the instantaneous turbulent flow eddies with today's computer technology. A common approach in the literature is to describe turbulent motion in terms of time-average quantities.
- One of the many turbulent models incorporated into the CFX-3D is the two-equation k-e model. This model has been highlighted in most fluid dynamics textbooks. The k-e model is based on Reynolds average equations and the eddy- viscosity concept. The general k- e model is not that effective in near- wall region. Therefore, a low Reynolds number and two equation k-e model coupled with a near-wall modeling scheme built in CFX 5.1 will be used in our flow simulations.
- the most time-consuming part of the computer simulation is construction of the grid system that resembles realistic 3-D oral-oropharyngeal-laryngeal airway geometry.
- a 3-D body-fitted oral airway grid system was constructed and simulated several cases for low Reynolds number flows.
- the computational oral airway geometry was reconstructed based on the information published by Cheng et al. (1997).
- the grid test was conducted to minimize numerical truncation errors.
- a final grid size was chosen for the production runs as a compromise between computational accuracy and the cost.
- arrays of 25x35 (approximately 700, in the preliminary study, 20x20 is used) particles, which are uniformly distributed in the cross-sectional area of the mouth entrance, were launched simultaneously. The positions of these particles in the airflow was then be computed and tracked all the way to deposition point. The total and regional particle deposition efficiencies was computed.
- the CFX-3D software serves the basic function of simulating particle trajectories.
- the effects of Brownian diffusion were not included in the trajectory model. This effect could be important for submicron particle (i.e., some aerosols generated by nebulizer). Therefore, a customized trajectory code was needed.
- the Monte Carlo method was typically used in the customized code. It does take particle Brownian diffusion into account; however, the inherent 'random' nature of the method makes the deposition efficiency computing difficult, particularly for aerosols of smaller sizes. Particles ejected at the same location in the steady flow will always follow different paths and end up with different destinations at every-and-each simulation. Therefore, this method can't be used to generate the needed particle destination information, which is a key component of the proposed research.
- a unique trajectory mapping approach was modified to predict particle deposition efficiency in airways. This involved certain works of modifying source code and incorporating this model into the software. Brownian diffusion was accounted for using an effective particle radius concept. This effective radius is defined such that the apparent size of a particle being tracked grows in time according to the probability of not finding its center inside an exclusion sphere. This approach was uniformly applicable to all particle sizes with diffusion influence diminishing in importance as physical particle size increases. This method takes into account the Brownian diffusion effects, and at the same time, provides detailed spatial particle deposition patterns.
- Monte Carlo method was also used to provide the benchmark results for the proposed unified trajectory simulations. Monte Carlo method is a reliable and proven method, especially for larger particles.
- Monte Carlo method is a reliable and proven method, especially for larger particles.
- the physical meaning of the constant was the probability of aerosol that will diffuse to the outside the effective radius. This constant equals 0.65 for straight conducts (Zhang and Lessmann, 1997). It showed that this constant is insensitive to different variables and can be applied to a wide range of particle size (0.001 to 5 micron), different flow type (parabolic and plug), different pipe size, and different geometry (circular, square and other polygonal cross- sectional geometry).
- FIG. 8 is a breakaway perspective view of an embodiment of the invention, wherein an inhaler nozzle 10 is comprised of a housing 12.
- the inner surface 20 of the housing 12 is configured to facilitate the delivery of a medicated aerosol to the lungs of a user when the medicated aerosol is forced through the housing 12.
- the inner surface 20 comprises a lower arcuate section 30 and upper section 40.
- the upper section 40 comprises a first arcuate portion 42 and a second arcuate portion 44.
- the first arcuate portion 42 and the second arcuate portion 44 are joined together to form a ridge a ridge 46.
- Both the lower arcuate section 30 and the upper section 40 can extend along the entire length L of the housing 12 or optionally can extend along at least a portion of the length L of the housing.
- the lower arcuate section 30 can extend along the entire length L of the housing and the upper section 40 can extend along at least a portion of the length L of the housing or vice versa.
- FIG. 9A shows the front end view of FIG. 8.
- FIG. 9B is a sectional view FIG. 1 taken along lines 9B. wherein the upper section 40 extends downwardly along the entire length L of the inhaler nozzle 10 toward the lower arcuate section 30 at an angle within the range of between 5° to 40°, preferably 30°, to the vertical axis Y of the inhaler nozzle 10.
- FIG. 9C is a rear end view of FIG. 8.
- FIG. 1OA is a front end view of an alternative embodiment of FIG. 1.
- FIG. 10B is a sectional view of FIG. 1OA taken along lines 1OB wherein the upper section 40 extends downwardly along about half the length L of the inhaler nozzle 10 toward the lower arcuate section 30 at an angle within the range of between 5° to 40°, preferably 30°, to the vertical axis Y of the inhaler nozzle 10.
- FIG. 1OC is a rear end view of FIG. 1OA.
- An alternative embodiment is shown in including the front end view, See FIG. HA.
- FIG. HB is a sectional view of FIG.
- the housing 12 comprises a first segment 50 having a top and bottom surface 52, 54 and a second segment 60 having a top and bottom surface 62, 64.
- the top surface 62 extends upwardly from the top surface 52 at an angle within the range of between 5 ° to 40°, preferably 30°, from the horizontal axis X of the first segment 50.
- FIG. HC is a rear end view of FIG. 11C.
- FIG. 12A is a front end view of yet another embodiment of FIG. 1.
- FIG. 12B is a sectional view of FIG. 12A taken along lines 12B.
- the inhaler nozzle 10 comprises a collar 80 which collar 80 is adapted to frictionally receive a tube 70 having a length A.
- the length A is positioned at a right angle to the length L inhaler nozzle 10.
- Suitable moldable materials used to construct the inhaler nozzle 10 include moldable plastics.
- the oral airway model used in this study duplicates a physiologically realistic human airway morphology without any modifications. It was constructed from scanning pictures, which had been taken from a healthy human volunteer by using MRI (Magnetic Resonance Imaging) and provided by the Lovelace Respiratory Research Institute. It was then reconstructed into a three-dimensional configuration in our Laboratory both virtually (numerically) and physically.
- the oral airway model consisted of the mouth cavity, the pharyngeal cavity and the pharynx as shown in Fig. 13.
- the airway model was constructed from 61 clay segments with a thickness of 3 mm each.
- the original database was in digital format containing tens of thousands of points which represent the whole oral airway geometry; these points have been divided into three parts, and each part has been sliced into different cross sections In the first part, all the points in each cross section have the same Y-axis value with a thickness of 3 mm each. In the second part, all the points in each cross section have the same angle (0) forming a 90-degree bends. In the third part, all the points in each cross section have the same Z-axis value with a thickness of 3 mm each, as it shown here in Figure 14.
- the silicone rubber compound which was purchased in its liquid state, was prepared by mixing the rubber base with the silicone. The amount of the silicone was controlled at 10% of the weight of the base (rubber). The mix was stirred with a stiff, flat ended metal spatula and then placed into a vacuum chamber. The compound was evacuated to entrap the air from the mixture by achieving 30 inches of mercury vacuum through a vacuum pump. The mixture was kept in the chamber under vacuum for 15 minutes. The volume of the mixture grew fast while being placed the vacuum; therefore the mixing bowl should not be filled more than its one-third volume capacity. Then, the mixture was poured into the clay hollow slowly and steadily; thus minimize entrapped air bubbles during the pouring process.
- the clay cast and the poured mixture were placed on the shaker for 5-10 minutes to release any air bubbles trapped inside the clay cast.
- the silicone rubber compound must be allowed to cure for 16-24 hours before removing the rubber mold from the clay cast; a petroleum jelly is applied on the cast internal surface to make it easy to remove the rubber mold from the clay cast.
- the solid rubber mold must be allowed to stay in the air for 24 hours before using it to achieve a full cure.
- the solid rubber mold was used to construct the oral air way cast by suspending the mold within an open glass box.
- the previous procedure for preparing the silicone rubber compound was used here.
- the silicon rubber mixture was poured in the glass box to construct the hollow human oral air way cast and used in our experimental study as shown in Fig. 16.
- Dry green fluorescent polymer microspheres which are made of polystyrene divinylbenzene (DVB), have a density of 1.05 g/cm 2 , and they were used to prepare this suspension. 30 mg of fluorescent particles were mixed with 0.5 ml ethanol (95%) and placed in the sonicator for about 5 minutes to ensure fully dispersion of the agglomerated fluorescent particles in the ethanol. The volume of the prepared suspension is equal to 5% of the total volume of the commercial dummy inhaler See Fig 17. The prepared suspension was injected in the dummy commercial inhaler, and the whole system was then charged by 134-a by using the canister charging system. A mechanical shaker was used to mix the suspension with the 134-a.
- the dummy inhaler as it shown in Fig. 17 consists of three parts, the first, is the commercial canister, the second, is a clear tube, the third part, is a ball valve. These three parts connected to each other through pipe fittings.
- the commercial canister will be used as storage for more than 200 puffs and it is also consists of the metered dose valve, which is connected to the plastic actuator through the stem.
- the main reason for the clear plastic tube is to provide us with visual sight about the quality of the suspension inside the commercial canister.
- the ball valve was used as a shutoff valve to terminate or allow the propellant flow during the charging process.
- the dummy commercial inhaler was a good simulator to the actual commercial inhaler in the market.
- the canister charging system is a mechanical device which is used to charge or pressurize the dummy inhaler with the HFA propellant (134-a).
- This system consists of several parts as it shown in Fig. 18. This system contained three valves, valve I, valve II and valve DI, valve I is used to control, terminate and release the pressurized propellant from the propellant can to the dummy inhaler, valve II was connected to a vacuum pump, which was used to evacuate the dummy inhaler from the air before starting to inject the fluorescent suspension inside the dummy inhaler, valve HI is used to release the prepared suspension under the vacuum pressure through this valve to the dummy canister.
- a pressure gauge was installed next to the propellant can as an indicator to the level of the propellant inside the can.
- a pressurized 134-a propellant can is used to as storage to be used to charge the dummy canister when needed, this can has a shut off valve to control and terminate the propellant flow.
- the charging of the dummy canister process contained different steps, first, was to open all the shut off valves from the pressure gauge till the dummy canister (there were four valves to control the propellant flow), the second, was to apply a vacuum pressure through valve in to evacuate the air from the dummy canister, the third, was to allow the vacuum pressure to release the prepared suspension into the dummy inhaler through valve II, the fourth, is to open the can's valve to fill the dummy canister with the HFA 134-a, the fifth, is to close all the shut off valves and separate the dummy canister from the charging system.
- the dummy canister was filled with the propellant, and was easily seen through the clear tube.
- the experimental apparatus contained the oral airway model, the inhaler, inhaler positioning device, a vacuum pump, a flow meter, a flow rate regulator, valves, two expansion balloons and two breathing chambers as shown in Fig. 19.
- the reference breathing chamber was used to measure the reference/benchmark. This chamber was connected to a vacuum pump through the opening at the back.
- An expansion bag (the reference balloon) was placed inside the chamber and connected to the front opening from the inside. The front opening was exposed to the ambient pressure. When the vacuum pressure was applied to the chamber, the expansion bag expanded inside the reference breathing chamber and sucked the air and induced the air flow to the front opening. Four puffs was sprayed into the reference expansion bag during the expansion process of Fig. 19.
- the cast breathing chamber was connected to the vacuum pump through a side opening and to the oral airway cast through the top opening from the outside opening.
- An expansion balloon was placed inside the breathing chamber and connected to the outlet of the oral airway cast.
- the cast expansion bag expanded; the degree of vacuum determined the rate of balloon expansion, and in turn determined the rate of respiratory flow through the oral airway passage. Again, four puffs were sprayed into the oral airway geometry during the expansion of the cast balloon for aerosol deposition measurement.
- a flow meter was connected to the vacuum tube to measure the respiratory air flow rate.
- the flow meter was calibrated before the starting of the experiments.
- An air flow regulator was used to control the air flow rate representing a wide range of flow rates encountered in the aerosol therapy.
- An inhaler-positioning device was designed to hold and control the position of the dummy inhaler during the spray process.
- the device can position the dummy inhaler at different x-y-z positions as well as injection angles, which allowed one to study the effects of the mouthpiece position on the inhaler efficiency. With this structure, it was convenient to investigate the entrance angle effect, and the effects of lateral and the axial movement of the mouthpiece with respect to the entrance of the oral airway cast.
- Expansion bags were used to collect the deposited fluorescent particles and to measure indirectly the particles deposited in the oral airway cast.
- the expansion bags have an aerodynamic similarity with the human respiratory system. It was a simple, accurate and effective method in collecting the deposited fluorescent particles.
- a filter or filters are placed downstream of the airway models and collect the penetrated aerosols particles such as (Cheng, Y. S., Yazzie, A. S., Gao J., 2003).
- the quantity/percentage of particles penetration would be measured by either comparing the weights of the filter before and after the aerosol deposition experiment, or by measuring the fluorescent intensity of particles captured by the filter. If the radioactivity-labeled particles were used, the intensity of the radioactivity were measured.
- One balloon was attached to outlet of the airway model and placed inside the cast breathing chamber. Another balloon was attached to the inlet of the reference breathing chamber. Respiratory flow rates (including both steady and transient airflows) were controlled by the rate of the balloon expansion, which is in turn controlled by the vacuum pump. All fluorescent particles were deposited inside the reference balloon or penetrated through the airway model to the cast balloon were captured inside the surface of these balloons. After the pre-determined number of inhaler puffs, the vacuum pump was stopped and balloon released air (or shrunk) at the controlled rate until it reached its natural un-inflated shape. Then, fixed amounts of DI water was poured into and ring-off the aerosols deposited on the balloons surfaces.
- the particle deposition efficiency of the oral airway cast is defined as:
- a calibration curve was obtained for measuring particle mass concentration vs. spectrophotometer readings, which is shown in Fig. 20.
- Figure 8 shows that there existed a linear relationship between the spectrophotometer reading and the particle volume fraction.
- the calibration curve was used to quantify the various deposition measurements, such as the human oral airway deposition fraction, fraction of the particles penetrating the cast, and spacer deposition fraction. Fixed volumes of DI water were used to wash out the particles deposited either in the collecting balloon, or in the oral cast, or in the reference balloon for various measurements.
- the spectrophotometer readings were directly correlated to the fluorescent particles existence. To assure there was no existence of fluorescent before hand, 3 ml of DI water was used to ring inside the balloon before it was used in the experiment. The spectrophotometer reading, which called 'back ground readings' was negligible. It was also found that the balloons materials used had no effect on the spectrophotometer readings.
- the prepared fluorescent-R134a suspension was not sensible to the time. Same balloon spray and measurement procedures were repeated two weeks apart under the other identical conditions, the difference in spectrophotometer readings is less than + 5.6% .
- the human oral airway cast Before each test had begun, the human oral airway cast must be cleaned by using the Ethanol to remove excess dust and dried fluorescent particles.
- the oral airway cast was first coated by Ethanol and scrubbed by using brush. This washing and scrubbing procedure was repeated several times, and the cast was left to dry out, then the inner surface of the human oral airway cast was coated by petroleum jelly to prevent the fluorescent particles from bouncing off the surface and reentering the respiratory flow during the experiments.
- the two halves of the oral cast were then properly aligned and fastened together by using silicon rubber compound.
- the cast was then left for 24 hours to allow full cure of the silicon rubber compound.
- the cast balloon was then attached at the lower end of the oral cast. This balloon was washed down first and dried to remove any excess powder inside the balloon.
- the oral cast and the attached balloon was placed at the top of the cast breathing chamber inlet and sealed by using silicon rubber compound. This balloon will be called "cast balloon".
- the oral cast will be outside the chamber and the cast balloon will be inside the chamber.
- Another balloon was placed at the inlet of the reference chamber. This balloon will be called “reference balloon”.
- the air flow rate was adjusted through the air flow controller (valve).
- the reference and the cast balloons were allowed to expand and the shrinking time was recorded (must be 10 minutes to proceed with the experiments).
- the dummy inhaler was placed on a mechanical shaker to disperse any agglomerated fluorescent particles; the time between shaking the dummy inhaler and spray inside the cast or the reference balloon is less than 30 seconds.
- the dummy inhaler was placed on the inhaler holder before spraying inside the cast balloon. Four puffs were sprayed inside the reference and the cast balloon respectively after the balloon expansion was steady. Next, the balloons were allowed to fully shrink. The two balloons were removed from the breathing chambers.
- each balloon were labeled, and the particles-DI water solution be collected by using a clean syringe.
- the concentration of the fluorescent particles in the collected samples was then measured by the fluorescence spectrophotometer.
- the fluorescent spectrophotometer operated according to the guidelines of the currently loaded program. A specific program had to be developed and tested for the fluorescent particles under study. Concentration readings are recorded for each sample and this completes the procedure for each experiments.
- Line graph charts of Fig. 21 and Fig. 22 show the particle penetration efficiencies for the flow rates of 30 L/min, 60 L/min and 90 L/min, with mouthpiece diameters equal to 20 mm and 16 mm, respectively. It is noted that flow rate of 30 L/min represents the typical breathing intensity for a human adult at the light activity and 60 L/min represents that at the heavy activity,
- the particle penetration efficiencies decreased with the increase in flow rates.
- the particle-R134a suspension sprayed out of the inhaler nozzle have a much higher initial velocity than that of the respiratory flow and gradually slow down by the surrounding air flow due to flow shear stress or drag force.
- the lower of the air flow rates the larger the difference between the air velocity and particles initial velocity, and therefore, and the greater drag force will be.
- the velocity of the aerosol particles will be reduced. It is known that the inertia impaction is the dominant mechanism of particle deposition in oral airways.
- the inertial parameter is function of particle density, particle diameter and air flow rate.
- particle velocity is the major variable in the inertia impaction parameter.
- Figs 21 and 22 show that the correlations of the particle penetration efficiencies with the airflow rates are highly nonlinear. For both cases of 20- mm mouthpiece diameters in Fig. 21 and 16-mm diameter in Fig 22, penetration efficiencies are almost tripled (from 6.1 % to 15.8%) when flow rates decreased from 90 L/min to 60 L/min in the case of 16 mm diameter, The further enhancements in penetration efficiency become smaller; it is less than doubled (from 15.8% to 25.8%) when flow rates decrease from 60 L/min to 30 L/min in the case of 16 mm diameter.
- Fig. 23 shows the relative increasing in the penetration efficiency at different respiratory flow rates in both diameter 16 mm and 20 mm. flow rate 90 L/m will be the reference in calculating the relative increase in the penetration efficiency. Relative increase is defined as:
- mouthpiece diameter is inversely proportional to the square of the channel size.
- T 2 U C
- r and u are channel radius and mean velocity, respectively. Therefore, particle velocity is inversely proportional to the square of the channel size.
- the 20-mm mouthpiece diameter will result in a lower aerosol droplets velocity than that of the 16 mm- mouthpiece diameter. Lower velocity associates with lower inertia impaction parameter, thus, less fluorescent particles will deposited in the oral airway.
- Figure 23 (#65-See part 3, Figure 23)demonstrate the relative efficiency enhancement when the entrance angle increased from 0 degree to 20 degree.
- Figure 23 also shown that the entrance angle effect is very apparent at higher flow rates (90 L/min) compare with lower flow rates (30 L/min)
- the relative efficiency increasment from 0 degree angle to 20 degree angle is 193.8% , 40.8% and 15.5% at 90 L/min, 60 L/min and 30L/min respectively at mouthpiece diameter of 16mm.
- the relative efficiency increasment is 152.1 % , 45.5% and 9.8% at 90 L/min, 60 L/min and 30L/min respectively.
- the patient should use the deep and slow breathing.
- the reduction of the particle velocity is an effective method to increase particle penetration efficiencies.
- a larger diameter mouthpiece design is preferred as long as it can be comfortably fit into the patient's mouth.
- a high efficiency mouthpiece design should incorporate an outlet with slightly upward angle.
- Fig. 1 shows an innovated simple needle-based jet spreading device located in side the mouthpiece.
- a needle of approximately 0.5 mm diameter is placed horizontally across the mouthpiece diameter with a distance approximately of 1 mm in front of the canister nozzle.
- High velocity R134a-particle jet rushing through the canister nozzle is divided into two streams when bypassing the needle.
- the needle serves two functions: it reduces the jet linear momentum by absorbing the direct impaction and it makes the spray more diffusive by slightly modifying the jet direction.
- Experimental measurement shows that the additional deposition of aerosols, on the surface of the needle and inner surface of the mouthpiece caused by the needle structure, is insignificant.
- Panels A and B are graphs of the aerosol penetration efficiency using the original inhaler mouthpiece at flow rates of 30, 60 and 90 L/min with the diameters of 16 mm and 20 mm, respectively.
- the particle-R134a suspension sprayed out of the inhaler nozzle had a much higher initial velocity than that of the respiratory air flow and gradually slowed down by the surrounding air flow due to viscous shear stress or drag force. When the airflow velocity was lower, the difference between the air and particles initial velocity was greater.
- the larger mouthpiece diameter also corresponds to lower aerosol velocity.
- Q 30 L/min
- D 20 mm
- the Metered-Dose-Inhaler spray angle has a strong effect on the aerosol penetration efficiency through the oral airway cast. Placing the MDI inhaler with a slightly upward angle can significantly decrease the particle deposition in the oral airways cast. An optimum angle exists which can maximize the particle penetration efficiency through the oral airway. This conclusion is independent of respiratory rate and mouthpiece diameter.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89295207P | 2007-03-05 | 2007-03-05 | |
US60/892,952 | 2007-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009005546A1 true WO2009005546A1 (en) | 2009-01-08 |
Family
ID=40226383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/002989 WO2009005546A1 (en) | 2007-03-05 | 2008-03-05 | High efficiency mouthpiece/adaptor for inhalers |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009005546A1 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011056889A1 (en) * | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
US8424518B2 (en) | 2008-06-13 | 2013-04-23 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
US9220687B2 (en) | 2008-12-29 | 2015-12-29 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
US9241903B2 (en) | 2006-02-22 | 2016-01-26 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US9283193B2 (en) | 2005-09-14 | 2016-03-15 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US9358352B2 (en) | 2008-06-13 | 2016-06-07 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US9364436B2 (en) | 2011-06-17 | 2016-06-14 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US9630930B2 (en) | 2009-06-12 | 2017-04-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
US9675674B2 (en) | 2004-08-23 | 2017-06-13 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US9700690B2 (en) | 2002-03-20 | 2017-07-11 | Mannkind Corporation | Inhalation apparatus |
US9796688B2 (en) | 2004-08-20 | 2017-10-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9801925B2 (en) | 1999-06-29 | 2017-10-31 | Mannkind Corporation | Potentiation of glucose elimination |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
US9943571B2 (en) | 2008-08-11 | 2018-04-17 | Mannkind Corporation | Use of ultrarapid acting insulin |
US9983108B2 (en) | 2009-03-11 | 2018-05-29 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10421729B2 (en) | 2013-03-15 | 2019-09-24 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US10625034B2 (en) | 2011-04-01 | 2020-04-21 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
EP3930807B1 (en) * | 2019-02-27 | 2023-11-08 | NuvoAir AB | A method and a device for estimating an amount of a powder shaped material passing a bend in a flow channel |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5178138A (en) * | 1990-09-11 | 1993-01-12 | Walstrom Dennis R | Drug delivery device |
-
2008
- 2008-03-05 WO PCT/US2008/002989 patent/WO2009005546A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5178138A (en) * | 1990-09-11 | 1993-01-12 | Walstrom Dennis R | Drug delivery device |
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9801925B2 (en) | 1999-06-29 | 2017-10-31 | Mannkind Corporation | Potentiation of glucose elimination |
US9700690B2 (en) | 2002-03-20 | 2017-07-11 | Mannkind Corporation | Inhalation apparatus |
US9796688B2 (en) | 2004-08-20 | 2017-10-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US10130685B2 (en) | 2004-08-23 | 2018-11-20 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US9675674B2 (en) | 2004-08-23 | 2017-06-13 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US10143655B2 (en) | 2005-09-14 | 2018-12-04 | Mannkind Corporation | Method of drug formulation |
US9717689B2 (en) | 2005-09-14 | 2017-08-01 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US9446001B2 (en) | 2005-09-14 | 2016-09-20 | Mannkind Corporation | Increasing drug affinity for crystalline microparticle surfaces |
US9283193B2 (en) | 2005-09-14 | 2016-03-15 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US9241903B2 (en) | 2006-02-22 | 2016-01-26 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US10130581B2 (en) | 2006-02-22 | 2018-11-20 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US9339615B2 (en) | 2008-06-13 | 2016-05-17 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9511198B2 (en) | 2008-06-13 | 2016-12-06 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10342938B2 (en) | 2008-06-13 | 2019-07-09 | Mannkind Corporation | Dry powder drug delivery system |
US9358352B2 (en) | 2008-06-13 | 2016-06-07 | Mannkind Corporation | Dry powder drug delivery system and methods |
US8636001B2 (en) | 2008-06-13 | 2014-01-28 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US8424518B2 (en) | 2008-06-13 | 2013-04-23 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9393372B2 (en) | 2008-06-13 | 2016-07-19 | Mannkind Corporation | Dry powder drug delivery system |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
US9446133B2 (en) | 2008-06-13 | 2016-09-20 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US8912193B2 (en) | 2008-06-13 | 2014-12-16 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10751488B2 (en) | 2008-06-13 | 2020-08-25 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10201672B2 (en) | 2008-06-13 | 2019-02-12 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US8499757B2 (en) | 2008-06-13 | 2013-08-06 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9662461B2 (en) | 2008-06-13 | 2017-05-30 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9192675B2 (en) | 2008-06-13 | 2015-11-24 | Mankind Corporation | Dry powder inhaler and system for drug delivery |
US10675421B2 (en) | 2008-06-20 | 2020-06-09 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US9943571B2 (en) | 2008-08-11 | 2018-04-17 | Mannkind Corporation | Use of ultrarapid acting insulin |
US9655850B2 (en) | 2008-12-29 | 2017-05-23 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9220687B2 (en) | 2008-12-29 | 2015-12-29 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US10172850B2 (en) | 2008-12-29 | 2019-01-08 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9983108B2 (en) | 2009-03-11 | 2018-05-29 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US9630930B2 (en) | 2009-06-12 | 2017-04-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
US9706944B2 (en) | 2009-11-03 | 2017-07-18 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
US9016147B2 (en) | 2009-11-03 | 2015-04-28 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
US20120247235A1 (en) * | 2009-11-03 | 2012-10-04 | Mannkind Corporation | apparatus and method for simulating inhalation efforts |
WO2011056889A1 (en) * | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
US10625034B2 (en) | 2011-04-01 | 2020-04-21 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
US10130709B2 (en) | 2011-06-17 | 2018-11-20 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US9364436B2 (en) | 2011-06-17 | 2016-06-14 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US10258664B2 (en) | 2011-10-24 | 2019-04-16 | Mannkind Corporation | Methods and compositions for treating pain |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
US9610351B2 (en) | 2011-10-24 | 2017-04-04 | Mannkind Corporation | Methods and compositions for treating pain |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
US10421729B2 (en) | 2013-03-15 | 2019-09-24 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
EP3930807B1 (en) * | 2019-02-27 | 2023-11-08 | NuvoAir AB | A method and a device for estimating an amount of a powder shaped material passing a bend in a flow channel |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009005546A1 (en) | High efficiency mouthpiece/adaptor for inhalers | |
Stahlhofen et al. | Intercomparison of experimental regional aerosol deposition data | |
CN107271337B (en) | Human alveolus aerosol deposition measurement experiment system | |
Kwok et al. | Delivery of inhalation drugs to children for asthma and other respiratory diseases | |
Javaheri et al. | An idealized geometry that mimics average infant nasal airway deposition | |
Carrigy et al. | Pediatric in vitro and in silico models of deposition via oral and nasal inhalation | |
Xi et al. | Nasal and olfactory deposition with normal and bidirectional intranasal delivery techniques: In vitro tests and numerical simulations | |
CN104138630B (en) | Respiratory tract drug delivery device and method | |
Bass et al. | High-efficiency dry powder aerosol delivery to children: Review and application of new technologies | |
Farkas et al. | Development of an inline dry powder inhaler that requires low air volume | |
Ali | Pulmonary drug delivery | |
Wang | Inhaled particles | |
Fonceca et al. | Drug administration by inhalation in children | |
Clark et al. | In vitro testing of pharmaceutical aerosols and predicting lung deposition from in vitro measurements | |
Ali et al. | Electrostatic charge effect on respirable aerosol particle deposition in a cadaver based throat cast replica | |
Mitchell et al. | Clinically relevant in vitro testing of orally inhaled products—bridging the gap between the lab and the patient | |
Martonen | Aerosol therapy implications of particle deposition patterns in simulated human airways | |
Fadl et al. | Effects of MDI spray angle on aerosol penetration efficiency through an oral airway cast | |
Kugler et al. | Determination of emitted particle characteristics and upper airway deposition of Symbicort® Turbuhaler® dry powder inhaler | |
Cui | CFD Study of the flow field and particle dispersion and deposition in the upper human respiratory system | |
Coates et al. | How many infective viral particles are necessary for successful mass measles immunization by aerosol? | |
Dai et al. | Numerical study of effects of device design on drug delivery efficiency for an active dry powder inhaler | |
US20090285763A1 (en) | Infant aerosol drug delivery systems and methods | |
Finlay | Inertial sizing of aerosol inhaled during pediatric tidal breathing from an MDI with attached holding chamber | |
Sbirlea-Apiou et al. | Deposition mechanics of pharmaceutical particles in human airways |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08794317 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08794317 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM1205A SENT 17.11.2009) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08794317 Country of ref document: EP Kind code of ref document: A1 |